title: Inactivated human rotavirus vaccine induces heterotypic antibody response: correction and development of IgG avidity assay.
abstract: To improve lower efficacy among infants in low income countries and the safety (e.g., rare but severe intussusception) of live oral rotavirus vaccines, we have developed CDC-9 strain with G1P[8] specificity as a candidate inactivated rotavirus vaccine (IRV). This IRV of 3 doses elicits high titers of IgG, neutralizing activity to homotypic and heterotypic human strains and IgG avidity in guinea pigs, thus is a promising alternative to enhance global immunization against rotavirus in children.
authors.affiliation: a Division of Viral Diseases ; Centers for Disease Control and Prevention ; Atlanta , GA USA.
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Velasquez
authors.forename: Yuhuan
authors.initials: Y
authors.lastname: Wang
authors.forename: Baoming
authors.initials: B
authors.lastname: Jiang
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D000915:Antibody Affinity; D006168:Guinea Pigs; D064789:Immunity, Heterologous; D007074:Immunoglobulin G / Q000097:blood*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination / Q000379:methods; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D022243:Rotavirus Vaccines; D015164:Vaccines, Inactivated
keywords: CDC-9; IRV; IgG-avidity; heterotypic protection; rotavirus